Velsipity Launch Webinar
17
th October 2024
18:00-19:15
Velsipity is indicated for the treatment of patients 16 years of age
and older with moderately to severely active ulcerative colitis (UC)
who have had an inadequate response, lost response, or were
intolerant to either conventional therapy, or a biological agent.
Professor Charlie Lees
Charlie is Professor of Gastroenterology at
the University of Edinburgh, a UK Research
and Innovation Future Leaders Fellow and
Consultant Gastroenterologist in the
Edinburgh IBD Unit.
Professor Peter Irving
Peter is a Consultant Gastroenterologist
at Guy's and St Thomas' Hospital